Evidence map›Paper›PMID 34568071›Full record

ArticleFrontiers in oncology2021

Haixia Guo, Na Li, Yaping Sun, Cuiling Wu, Huixia Deng, Ling Xu, Xu Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Frontiers in oncology · 2024
    Article
  2. Frontiers in genetics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Haixia GuoDepartment of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Na LiDepartment of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yaping SunInstitute of Systems Biology, Shenzhen Bay Laboratory, Shenzhen, China.
Cuiling WuDepartment of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Huixia DengDepartment of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Ling XuDepartment of Hematology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Xu YangDepartment of Hematology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Southern Medical University · CNGuangzhou Medical University · CNNanfang Hospital · CNShenzhen Bay Laboratory · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAlthough

methodsA total of 687 pediatric ALL cases and 971 cancer-free controls from two hospitals in South China were recruited. A case-control study by genotyping three SNPs in the

resultsOur study demonstrated that rs285207 was related to a decreased ALL risk (adjusted OR = 0.78; 95% CI = 0.63-0.97,

conclusionIn this study, we revealed that rs285207 polymorphism decreased the ALL risk in children, and rs285207 might alter the binding to IKZF1, which indicated that the

Indexed as

acute lymphoblastic leukemia (ALL)childrenIKZF1MYBL2single nucleotide polymorphisms (SNPs)susceptibility

Identifiers

PMID34568071
PMCPMC8456030
OpenAlexW3198040330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.